Clinical Trials Logo

Clinical Trial Summary

The spontaneous passage rate for ureteral stone less than 1cm causing acute ureteral obstruction is about 50%. Previous Cochrane review has concluded that alpha blocker is likely to increase stone passage rate, reduce time to stone passage, analgesic use and hospitalisations. The European Association of Urology Guideline also recommends giving alpha blockers as Medical Expulsive Therapy to patients with distal ureteric stones >5mm. However there is heterogeneity in different alpha blockers. Silodosin is a recently introduced selective alpha blocker which has a much higher selectivity for the alpha-1-A receptor (17-fold compared with tamsulosin). From previous animal studies, ureteral contraction is mainly mediated by the alpha-1-A receptor, hence silodosin maybe more effective in increasing stone passage compared with tamsulosin. Previous studies and meta-analysis has shown superiority of silodosin over tamsulosin on earlier stone passage and less pain. However, there is no data on Chinese population. The investigators would like to compare the efficacy and side effect profile of Silodosin versus tamsulosin on improving stone passage rate and hence reduce rate of further intervention for stone clearance.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05570084
Study type Interventional
Source Princess Margaret Hospital, Hong Kong
Contact YI CHIU, MBBS(HK)
Phone 29901960
Email cy225@ha.org.hk
Status Recruiting
Phase Phase 3
Start date May 31, 2022
Completion date December 31, 2023

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03243682 - The Alternating Bidirectional Versus The Standard Approach During Shock Wave Lithotripsy For Renal And Upper Lumbar Ureteric Stones N/A
Completed NCT04594161 - Effectiveness of Drainage by PCN vs. JJ in Patients With Symptoms of Obstructive Kidney Disease Caused by Urolithiasis N/A
Completed NCT04605315 - Indications and Outcomes in Kidney-ureteral Pediatric Lithiasis: Experience of Parma
Active, not recruiting NCT05759767 - The Efficacy and Safety of Medical Expulsive Therapy After Extracorporeal Shock Wave Lithotripsy (ESWL) in Pediatric Urolithiasis N/A
Completed NCT03388060 - (SWL) Versus (ODT) Versus Combined SWL And ODT For Radiolucent Stone N/A